← Leaderboards
Ming Hui Chen
Beth Israel Deaconess Medical Center
$4,823,776
Attributed
$4,823,776
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2022–25$2M$1.5M$1M$500K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$4,823,776 · 4
By mechanism
R01$4,823,776 · 3
M01$0 · 1
Top collaborators
No co-investigators on record.
Most similar at Beth Israel Deaconess Medical Center
Same institution · by research overlap
- Lewis C Cantley$35,988,650
- Stephen Paul Soltoff$5,621,506
- Xiao Zhen Zhou$3,160,397
- Xin Yuan$3,922,786
- Changmeng Cai$4,011,441
Others in their field
Top investigators on “Insight”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- James Dennis Neaton · Northwestern University$283,212,546
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$278,513,775
- Chanza Baytop · Westat, Inc.$271,217,917
- Richard K. Wilson · Washington University$200,435,757
Research focus
InsightGenetically Engineered MouseEventMalignant Neoplasm Of ProstateIn VivoMalignant NeoplasmsProstate Cancer ModelGeneticIn VitroCell LineCharacteristicsBiological ModelsBritish ColumbiaInvestigationCancer TherapyBiological MarkersCollaborationsClinical TrialsDesignCastrationClinicCell DeathAffectDrug Combinations
Grant awards (17)
Targeting Ferroptosis in Lethal RB1 Deficient Prostate Cancer$420,140
R01 · FY2025 · CA · contact PI
Engineering Large Chromosomal Deletions in Mice to Advance Precision Oncology$416,540
R01 · FY2025 · CA · contact PI
Developing A Novel Combinatorial Therapy for Lethal Neuroendocrine Prostate Cancer$396,130
R01 · FY2025 · CA · contact PI
Targeting Ferroptosis in Lethal RB1 Deficient Prostate Cancer$399,133
R01 · FY2024 · CA · contact PI
Engineering Large Chromosomal Deletions in Mice to Advance Precision Oncology$395,714
R01 · FY2024 · CA · contact PI
Developing A Novel Combinatorial Therapy for Lethal Neuroendocrine Prostate Cancer$376,323
R01 · FY2024 · CA · contact PI
Targeting Ferroptosis in Lethal RB1 Deficient Prostate Cancer$411,737
R01 · FY2023 · CA · contact PI
Engineering Large Chromosomal Deletions in Mice to Advance Precision Oncology$408,210
R01 · FY2023 · CA · contact PI
Developing A Novel Combinatorial Therapy for Lethal Neuroendocrine Prostate Cancer$377,730
R01 · FY2023 · CA · contact PI
Targeting Ferroptosis in Lethal RB1 Deficient Prostate Cancer$420,140
R01 · FY2022 · CA · contact PI
Engineering Large Chromosomal Deletions in Mice to Advance Precision Oncology$416,540
R01 · FY2022 · CA · contact PI
Developing A Novel Combinatorial Therapy for Lethal Neuroendocrine Prostate Cancer$385,439
R01 · FY2022 · CA · contact PI
HEART FUNCTION FOLLOWING TREATMENT OF HODGKIN'S DISEASE AND RADIATION$0
M01 · FY2002 · RR
HEART FUNCTION FOLLOWING TREATMENT OF HODGKIN'S DISEASE AND RADIATION$0
M01 · FY2001 · RR
HEART FUNCTION FOLLOWING TREATMENT OF HODGKIN'S DISEASE AND RADIATION$0
M01 · FY2000 · RR
HEART FUNCTION FOLLOWING TREATMENT OF HODGKIN'S DISEASE AND RADIATION$0
M01 · FY2000 · RR
HEART FUNCTION FOLLOWING TREATMENT OF HODGKIN'S DISEASE AND RADIATION$0
M01 · FY2000 · RR